Metastatic Castration-Resistant Prostate Cancer After Prior ARPI: Choosing the Next Treatment

Authored by Natalia Gandur, published on 2026-05-07 22:45:41.0

This algorithm guides next-line systemic treatment selection in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior exposure to an androgen receptor pathway inhibitor (ARPI), including abiraterone, enzalutamide, apalutamide, or darolutamide.The goal is to avoid a broad mCRPC overview and focus specifically on the practical sequencing question: After prior ARPI progression, what should be the next treatment?

Patient with mCRPC progressing after prior ARPI

Abiraterone, enzalutamide, apalutamide, or darolutamide given in mHSPC, nmCRPC, or mCRPC.
- Confirm and Reassess
  
  Castrate testosterone Radiographic/PSA/clinical progression Continue ADT Was ARPI stopped for intolerance rather than progression?
  - Consider switch to alternative ARPI
    
    Only if stopped for intolerance and not true progression
  - Comprehensive Reassessment Before Choosing Next Therapy
    
    Prior docetaxel exposure Prior ARPI setting and duration of benefit Symptoms and disease tempo Visceral metastases (especially liver) Performance status / frailty Marrow reserve Neuropathy Renal and hepatic function Patient goals and preference Access / logistics BRCA1/2 and other HRR alterations (PALB2, CDK12, ATM, CHEK2, etc.) MSI-H/dMMR / TMB-high PSMA PET status and eligibility for Lu-177–PSMA Aggressive variant / neuroendocrine features
    - Biomarker / Phenotype Override?
      - BRCA1/2 Alteration
        
        PARP inhibitor strategy favored (Strongest evidence in BRCA1/2)
      - Non-BRCA HRR Alteration
        
        PALB2 or selected CDK12: consider PARP inhibitor or clinical trial ATM, CHEK2 or others: clinical trial or standard non-PARP option favored
      - MSI-H / dMMR / TMB-high
        
        Immunotherapy (pembrolizumab) considered (tumor-agnostic indication)
      - Aggressive Variant / Neuroendocrine Features
        
        Low PSA / high burden Liver metastases Lytic lesions Rapid progression Elevated LDH Consider: biopsy, Platinum-based chemotherapy, Clinical trial
        
        Specialist input recommended (Clinical trial strongly considered)
      - Prior Docetaxel?
        
        NO PRIOR DOCETAXEL
        
        Docetaxel (Preferred default for fit patients)
        
        Symptomatic or rapid progression High-volume disease Visceral disease No actionable biomarker Adequate PS and marrow reserve Evidence: Strong (Standard of care)
        
        PSMA-Negative or Discordant Disease
        
        Lu-177–PSMA generally not appropriate Consider cabazitaxel, biopsy, platinum (if aggressive variant), or clinical trial Evaluate for aggressive variant / neuroendocrine disease
        
        Reassess Continually
        
        Monitor response, toxicity, quality of life Reassess goals, access, and clinical trials at each decision point Consider next-line options based on prior therapies, response, and evolving evidence
        
        Lu-177–PSMA (Selected patients)
        
        PSMA PET-positive No significant PSMA-negative mismatch Eligible and available Delaying taxane is clinically appropriate Adequate marrow and renal function Evidence: Evolving (PSMAfore)
        
        PSMA-Negative or Discordant Disease
        
        Lu-177–PSMA generally not appropriate Consider cabazitaxel, biopsy, platinum (if aggressive variant), or clinical trial Evaluate for aggressive variant / neuroendocrine disease
        
        Reassess Continually
        
        Monitor response, toxicity, quality of life Reassess goals, access, and clinical trials at each decision point Consider next-line options based on prior therapies, response, and evolving evidence
        
        Clinical Trial
        
        Non-BRCA HRR alterations PSMA-negative disease Aggressive biology Patient preference Evidence: Variable (Depends on study)
        
        PSMA-Negative or Discordant Disease
        
        Lu-177–PSMA generally not appropriate Consider cabazitaxel, biopsy, platinum (if aggressive variant), or clinical trial Evaluate for aggressive variant / neuroendocrine disease
        
        Reassess Continually
        
        Monitor response, toxicity, quality of life Reassess goals, access, and clinical trials at each decision point Consider next-line options based on prior therapies, response, and evolving evidence
        
        PRIOR DOCETAXEL
        
        Cabazitaxel (Preferred default in most patients)
        
        Progression within 12 months on ARPI Fit for additional taxane Adequate marrow reserve No prohibitive neuropathy Evidence: Strong (CARD)
        
        Frail / Poor Performance Status / Poor Marrow Reserve
        
        Individualize: goals of care, symptoms, life expectancy Consider less intensive systemic therapy Best supportive care and symptom control Palliative radiation / bone-directed therapy as needed
        
        Reassess Continually
        
        Monitor response, toxicity, quality of life Reassess goals, access, and clinical trials at each decision point Consider next-line options based on prior therapies, response, and evolving evidence
        
        Lu-177–PSMA (Selected patients)
        
        PSMA PET-positive No mismatch Adequate marrow reserve Adequate renal function Eligible and available Access / logistics feasible Evidence: Strong (VISION, TheraP)
        
        Frail / Poor Performance Status / Poor Marrow Reserve
        
        Individualize: goals of care, symptoms, life expectancy Consider less intensive systemic therapy Best supportive care and symptom control Palliative radiation / bone-directed therapy as needed
        
        Reassess Continually
        
        Monitor response, toxicity, quality of life Reassess goals, access, and clinical trials at each decision point Consider next-line options based on prior therapies, response, and evolving evidence
        
        Other Options
        
        PARP inhibitor if BRCA/selected HRR alteration Clinical trial Consider biopsy if transformation suspected Evidence: Variable (Depends on option)
        
        Frail / Poor Performance Status / Poor Marrow Reserve
        
        Individualize: goals of care, symptoms, life expectancy Consider less intensive systemic therapy Best supportive care and symptom control Palliative radiation / bone-directed therapy as needed
        
        Reassess Continually
        
        Monitor response, toxicity, quality of life Reassess goals, access, and clinical trials at each decision point Consider next-line options based on prior therapies, response, and evolving evidence
KEY PRINCIPLES

✓ Avoid routine ARPI-to-ARPI switching after true progression ✓ Molecular testing and PSMA PET early in the pathway ✓ Match treatment intensity to disease tempo and patient fitness ✓ Clinical trial is a recurring option throughout the journey